

**REMARKS****Status of Claims**

Claims 1-29 are pending after entry of this paper. Claims 4-5, 7-8, 14-17, 19, 21-29 have been withdrawn without prejudice. Applicants reserve the right to pursue withdrawn and cancelled claims in a divisional or continuing application.

Claim 20 has been amended to delete reference to the antibody described in withdrawn claims 7-9.

No new matter has been introduced by these amendments.

**Response to Restriction Requirement under 35 U.S.C. §121 and §372**

In the Official Action, restriction under 35 U.S.C. §121 and §372 is required to one of the following eleven groups of inventions:

Group I: Claims 1-3, 6, 10-13, 18, 20 (in part), drawn to DNA which comprises a base sequence shown by SEQ ID NO: 1 or a sequence containing part of the sequence, a host cell, and a method for producing polypeptide.

Group II: Claims 4 and 5, drawn to a polypeptide which comprises SEQ ID NO: 2 or a variant thereof.

Group III: Claims 7-9, 20 (in part), drawn to an antibody.

Group IV: Claims 14, drawn to a method for screening a substance having a glucose and/or fructose transporter function-regulation activity.

Group V: Claims 15 and 16, drawn to a non-human animal model which develops renal diabetes caused by a defect in renal glucose reabsorption.

Group VI: Claims 17, drawn to a method for screening a preventive/therapeutic drug for renal diabetes caused by a defect in glucose reabsorption.

Group VII: Claims 19, drawn to a microarray or a DNA chip for diagnosing glucose and/or fructose transporter function.

Group VIII: Claims 21 and 22, drawn to a method for diagnosing glucose and/or fructose transporter function by measuring its gene expression using a probe.

Group IX: Claims 23 and 24, drawn to a method for diagnosing glucose and/or fructose transporter function by measuring the polypeptide using an antibody.

Group X: Claims 25, drawn to a method for diagnosing glucose and/or fructose transporter function by measuring the transporter function in a renal disease.

Group XI: Claims 26-29, drawn to a method for regulating glucose and/or fructose transporter function in an animal tissue cell.

In response to the Restriction Requirement, applicants provisionally elect to prosecute **Group I** including claims 1-3, 6, 10-13, 18, 20 in part drawn to DNA which comprises a base sequence shown by SEQ ID NO: 1 or a sequence containing part of the sequence, a host cell, and a method for producing polypeptide without traverse.

### **CONCLUSION**

Based on the foregoing amendments and remarks, the applicants respectfully request reconsideration allowance of this application. Favorable action by the Examiner is earnestly solicited.

**AUTHORIZATION**


The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **13-4500**, Order No. 4439-4034.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **13-4500**, Order No. 4439-4034.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: October 17, 2007

By:

  
\_\_\_\_\_  
Evelyn M. Kwon  
Registration No. 54,246

Correspondence Address:  
MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281-2101  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile